Volume 29, issue 9, September 2022

158 articles in this issue

1. Cancer Genetics Moves out of Its Winter of Discontent

2. Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer: Exciting New Horizon in Early-Stage Lung Cancer Care

3. Complementary Roles of Screening and Nodule Programs for Early Detection of Lung Cancer in Diverse Populations

4. Evaluating and Embracing Modern Imaging Technology to Guide Sentinel Node Biopsy for Melanoma

5. I’ve Got Bad News and Bad News: The Cost of Colorectal Cancer Care

6. Can We Predict Surgical Futility/Cure in Gallbladder Cancer?

7. Another Signal from DEBIRI

8. Should We Completely Exclude Locoregional Therapy for the Primary Tumor from Our Clinical Practice in De Novo Metastatic Breast Cancer?

9. Editorial Comment on: One-Year Experience of Same-Day Mastectomy and Breast Reconstruction Protocol

10. Commentary on “Differences in the Clinicopathologic Behavior of Oncocytic Adrenocortical Neoplasms and Conventional Adrenocortical Carcinomas” by Shirali et al.

11. Defining Relevancy in Patient-Reported Outcomes for Lung Cancer Surgery

12. Improving Oncologic Outcomes for Esophageal Cancer After Open and Minimally Invasive Esophagectomy

13. The WASH (Water or Saline at High Volumes) Trial: A Randomized Trial to Assess the Survival Impact of Extensive Peritoneal Lavage Using Distilled Water or Saline at High Volumes After Pancreatic Resection for Pancreatic Ductal Adenocarcinoma

14. A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial)

15. The Impact of COVID-19-Related Delays on Surgical Management of Peritoneal Surface Malignancies

16. Is the Choosing Wisely Recommendation for Omission of Sentinel Lymph Node Biopsy Applicable for Invasive Lobular Carcinoma?

17. Inflammatory Breast Cancer: Durable Breast Cancer-Specific Survival for HER2-Positive Patients with a Pathologic Complete Response to Neoadjuvant Therapy

18. Financial Impact of Out-of-Pocket Costs Among Patients Undergoing Resection for Colorectal Carcinoma

19. ASO Author Reflections: The Financial Impact of Out-of-Pocket Costs Among Patients Undergoing Resection for Colorectal Carcinoma

20. ASO Visual Abstract: The Financial Impact of Out-of-Pocket Costs Among Patients Undergoing Resection for Colorectal Carcinoma

21. The Pivotal Leadership of Doctors R. Lee Clark and Murray M. Copeland in Transforming the Commission on Cancer (1955–1965)

22. Patterns and Impact of Fragmented Care in Stage II and III Gastric Cancer

23. ASO Author Reflections: Care Fragmentation in an Era of Centralization

24. ASO Visual Abstract: Patterns and Impact of Fragmented Care in Stages II and III Gastric Cancer

25. Correction to: Data-Driven Respectful Discourse in the Society of Surgical Oncology

27. Postmastectomy Breast Reconstruction Patterns at an Urban Academic Hospital and the Impact of Surgeon Gender

28. ASO Visual Abstract: Postmastectomy Breast Reconstruction Patterns at an Urban Academic Hospital and the Impact of Surgeon Gender

29. Early Recurrence in Resected Gallbladder Carcinoma: Clinical Impact and Its Preoperative Predictive Score

30. ASO Author Reflections: Preoperative Prediction Score for Early Recurrence of Resected Gallbladder Carcinoma and Consideration of Optimal Treatment Strategies

31. ASO Visual Abstract: Early Recurrence in Resected Gallbladder Carcinoma-Clinical Impact and Its Preoperative Predictive Score

32. Drug-Eluting Bead, Irinotecan Therapy of Unresectable Intrahepatic Cholangiocarcinoma (DELTIC) with Concomitant Systemic Gemcitabine and Cisplatin

33. ASO Visual Abstract: Drug-Eluting Beads with Irinotecan Therapy of Unresectable Intrahepatic Cholangiocarcinoma (DELTIC) with Concomitant Systemic Gemcitabine and Cisplatin

34. Increased Morbidity and Mortality After Hepatectomy for Colorectal Liver Metastases in Frail Patients is Largely Driven by Worse Outcomes After Minor Hepatectomy: It’s Not “Just a Wedge”

35. ASO Visual Abstract: Increased Morbidity and Mortality After Hepatectomy for Colorectal Liver Metastases in Frail Patients is Largely Driven by Worse Outcomes After Minor Hepatectomy: It is Not “Just a Wedge”

36. Trends and Disparities in Treatment Utilization for Early-Stage Hepatocellular Carcinoma in the Veteran Population

37. ASO Author Reflections: Disparities in Utilization of Curative-Intent Therapy for Veterans with Early-Stage HCC

38. ASO Visual Abstract: Trends and Disparities in Treatment Utilization for Early-Stage Hepatocellular Carcinoma in the Veteran Population

39. Preoperative Diagnosis of Lymph Node Metastasis of Perihilar Cholangiocarcinoma Using Diffusion-Weighted Magnetic Resonance Imaging

40. ASO Author Reflections: Importance of Preoperative Diagnosis of Lymph Node Metastasis in Perihilar Cholangiocarcinoma

41. ASO Visual Abstract: Preoperative Diagnosis of Lymph Node Metastasis of Perihilar Cholangiocarcinoma Using Diffusion-Weighted Magnetic Resonance Imaging

42. The Histopathological Growth Pattern of Colorectal Liver Metastases Impacts Local Recurrence Risk and the Adequate Width of the Surgical Margin

43. ASO Author Reflections: The Histopathological Growth Pattern of Colorectal Liver Metastases: A New Biomarker to Drive Surgical Strategy

44. ASO Visual Abstract: The Histopathological Growth Pattern of Colorectal Liver Metastases Impacts Local Recurrence Risk and the Adequate Width of the Surgical Margin

45. Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis

46. ASO Author Reflections: Usage of Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma

47. ASO Visual Abstract: Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma—A Systematic Review and Meta-analysis

48. Full Laparoscopic Vascular Reconstruction for Portal Tumoral Invasion During a Right Hepatectomy Using the Caudal Approach

49. ASO Author Reflections: A New Red Line Trespassed? Vascular Resection and Reconstruction No Longer a Contraindication for Minimally Invasive Liver Surgery

50. ASO Visual Abstract: Full Laparoscopic Vascular Reconstruction for Portal Tumoral Invasion During Right Hepatectomy Using the Caudal Approach

51. Laparoscopic Orthotopic Right Hemihepatectomy by Anterior Approach Combined with Inferior Vena Cava Thrombectomy

52. ASO Author Reflections: Reflections on the Treatment Strategy of Hepatocellular Carcinoma with Inferior Vena Cava Thrombus in the New Era

53. Indocyanine Green-Guided Laparoscopic Redo Surgery for Incidental T2a Gallbladder Cancer

54. ASO Author Reflections: Can Indocyanine Green Increase the Safety of Bile Duct Dissection and Thus Improve Regional Lymphadenectomy in Re-Do Surgery for Incidental Gallbladder Cancer?

55. Differences in Clinicopathologic Behavior of Oncocytic Adrenocortical Neoplasms and Conventional Adrenocortical Carcinomas

56. ASO Author Reflections: The Impact of Oncocytic Histology on Survival in Adrenocortical Carcinoma

57. ASO Visual Abstract: Differences in the Clinicopathologic Behavior of Oncocytic Adrenocortical Neoplasms and Conventional Adrenocortical Carcinomas

58.Radical Resection in Entero-Pancreatic Neuroendocrine Tumors: Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence

59. ASO Author Reflection: Risk of Recurrence After Radical Resection in Entero-Pancreatic Neuroendocrine Tumors

60. ASO Visual Abstract: Radical Resection in Enteropancreatic Neuroendocrine Tumors—Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence

61. Well-Differentiated Thyroid Cancer: Who Should Get Postoperative Radiation?

62. ASO Visual Abstract: Well Differentiated Thyroid Cancer-Who Should get Postoperative Radiation?

63. Establishment of Minimal Clinically Important Improvement for Patient-Reported Symptoms to Define Recovery After Video-Assisted Thoracoscopic Surgery

64. ASO Author Reflections: Using Minimal Clinically Important Improvement for Patient-Reported Symptoms to Define Recovery

65. ASO Visual Abstract: Establishment of Minimal Clinically Important Improvement for Patient-Reported Symptoms to Define Recovery After Video-Assisted Thoracoscopic Surgery

66. Population-Based Cohort Study from a Prospective National Registry: Better Long-Term Survival in Esophageal Cancer After Minimally Invasive Compared with Open Transthoracic Esophagectomy

67. ASO Author Reflections: Better Long-Term Survival in Esophageal Cancer After Minimally Invasive Versus Open Transthoracic Esophagectomy in Sweden: A Population-Based Cohort Study

68. ASO Visual Abstract: Population-Based Cohort Study from a Prospective National Registry-Better Long-Term Survival in Esophageal Cancer after Minimally Invasive Compared with Open Transthoracic Esophagectomy

69. Combined Mean Corpuscular Hemoglobin, Fibrinogen, and Albumin (MF-A) Is a Novel Prognostic Marker in Patients with Resectable Esophageal Squamous Cell Carcinoma

70. ASO Author Reflections: A Novel Blood-Based Predictor (MF-A) That Independently Influences the Prognosis of ESCC Patients Receiving Esophagectomy

71. ASO Visual Abstract: Combined Mean Corpuscular Hemoglobin, Fibrinogen, and Albumin (MF-A) Is a Novel Prognostic Marker in Patients with Resectable Esophageal Squamous Cell Carcinoma

72. Prognostic Impact of Postoperative Loss of Skeletal Muscle Mass in Patients Aged 70 Years or Older with Esophageal Cancer

73. ASO Author Reflections: Significance of Postoperative Loss of Skeletal Muscle Mass in Older Patients with Esophageal Cancer

74. ASO Visual Abstract: Prognostic Impact of Postoperative Loss of Skeletal Muscle Mass in Patients Aged 70 Years or Older with Esophageal Cancer

75. Risk Factors for Para-Aortic Lymph Node Metastasis in Esophagogastric Junction Cancer: Results from a Prospective Nationwide Multicenter Study

76. ASO Visual Abstract: Risk Factors for Para-Aortic Lymph Node Metastasis in Esophagogastric Junction Cancer: Results from a Prospective Nationwide Multicenter Study

77. Salvage Surgery for Recurrent Disease after Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma

78. Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma

79. ASO Author Reflections: Pure and Combined Surgically Resected Large Cell Neuroendocrine Carcinoma of Lung: Could They be Evaluated as a Single Entity?

80. Mapping of Lymph Node Metastasis From Thoracic Esophageal Cancer: A Retrospective Study

81. Impact of Early Jejunostomy Tube Feeding on Clinical Outcome and Parameters of Body Composition in Esophageal Cancer Patients Receiving Multimodal Therapy

82. ASO Visual Abstract: Impact of Early Jejunostomy Tube Feeding on Clinical Outcome and Parameters of Body Composition in Esophageal Cancer Patients Receiving Multimodal Therapy

83. Prognostic Impact of Using Combined Plasma Fibrinogen Level and Neutrophil-to-Lymphocyte Ratio in Resectable Non-small Cell Lung Cancer

84. ASO Author Reflections: Clinical Significance of Combined Plasma Fibrinogen Level and Neutrophil-to-Lymphocyte Ratio in Non-small Cell Lung Cancer

85. ASO Visual Abstract: Does Preoperative Corticosteroid Administration Improve the Short-Term Outcome of Minimally Invasive Esophagectomy for Esophageal Cancer? A Propensity Score-Matched Analysis

86. One-Year Experience of Same-Day Mastectomy and Breast Reconstruction Protocol

87. ASO Author Reflections: Reducing Length of Stay and Postoperative Opioid Administration in a Same-Day Approach to Breast Reconstruction

88. ASO Visual Abstract: One-Year Experience of Same-Day Mastectomy and Breast Reconstruction Protocol

89. Clinical Manifestations and Surgical Management of Breast Implant-Associated Anaplastic Large Cell Lymphoma: Beyond the NCCN Guidelines

90. ASO Visual Abstract: Clinical Manifestations and Surgical Management of Breast Implant-Associated Anaplastic Large Cell Lymphoma—Beyond the NCCN Guidelines

91. Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1–2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical Trial

92. ASO Visual Abstract: Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1-2 Breast Cancer Patients Presenting 1-2 Metastatic Sentinel Lymph Nodes: The Multicenter Randomized Clinical Trial SINODAR-ONE

93. Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67

94. ASO Visual Abstract: Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer—Effects of Age and Tumor Ki67

95. Rural-Urban Differences in Breast Cancer Surgical Delays in Medicare Beneficiaries

96. ASO Visual Abstract: Rural–Urban Differences in Breast Cancer Surgical Delays in Medicare Beneficiaries

97. Survival Nomogram for Young Breast Cancer Patients Based on the SEER Database and an External Validation Cohort

98. ASO Author Reflections: Simplified Nomogram Predictive of Survival for Young Breast Cancer Patients

99. ASO Visual Abstract: Survival Nomogram for Young Breast Cancer Patients Based on the SEER Database and an External Validation Cohort

100. Fertility Preservation in Young Women with Breast Cancer: Impact on Treatment and Outcomes

101. ASO Author Reflections: Oncologic Safety of Fertility Preservation

102. Home Recovery After Mastectomy: Review of Literature and Strategies for Implementation American Society of Breast Surgeons Working Group

103. ASO Author Reflections: Homing in on Safety—Home Recovery After Mastectomy

104. Primary-Site Local Therapy for Patients with De Novo Metastatic Breast Cancer: An Educational Review

105. Points to Consider Regarding Risk-Reducing Mastectomy in High-, Moderate-, and Low-Penetrance Gene Carriers

106. Power Analysis in Clinical Trial Design

107. Correction: Health-Related Quality of Life After Nipple-Sparing Mastectomy: Results From the INSPIRE Registry

108. Correction to: Primary-Site Local Therapy for Patients with De Novo Metastatic Breast Cancer: An Educational Review

109. The Impact of Low Skeletal Muscle Mass on Short- and Long-Term Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

110. ASO Visual Abstract: The Impact of Low Skeletal Muscle Mass on Short- and Long-Term Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

111. Disparities in Surgical Timing and Guideline-Adherent Staging Work-Up for Colon Cancer

112. ASO Visual Abstract: Disparities in Surgical Timing and Guideline-Adherent Staging Workup for Colon Cancer

113. Mesocolon Excision in Right Colon Cancer: Is it a Real Oncological Procedure or a Mere Surgical Act?

114. Letter to the Editor Reply: ‘Mesocolon Excision in Right Colon Cancer: Is it a Real Oncological Procedure or a Mere Surgical Act?’

115. Preventing Futile Liver Resection: Biology Should be Central in Patients’ Selection

116. Authors’ Reply to Preventing Futile Liver Resection: Biology Should be Central in Patients’ Selection

117. Analysis of Opioid Use in Patients Undergoing Open Versus Robotic Gastrectomy

118. ASO Author Reflections: Value of Robotic Surgery in the Era of Opioid Crisis

119. ASO Visual Abstract: Analysis of Opioid Use in Patients Undergoing Open Versus Robotic Gastrectomy

120. Applicative Limitations of Indocyanine Green Fluorescence Assistance to Laparoscopic Lymph Node Dissection in Total Gastrectomy for Cancer

121. ASO Author Reflections: Indocyanine Green Fluorescence to Optimize Lymphadenectomy in Gastric Cancer Surgery: Recommendations to Improve Radicality in D2 Lymphadenectomy

122. Is Prophylactic Splenectomy Necessary for Proximal Advanced Gastric Cancer Invading the Greater Curvature with Clinically Negative Splenic Hilar Lymph Node Metastasis? A Multi-Institutional Cohort Study (YCOG2003)

123. ASO Visual Abstract: Is Prophylactic Splenectomy Necessary for Proximal Advanced Gastric Cancer Invading the Greater Curvature with Clinically Negative Splenic Hilar Lymph Node Metastasis? A Multi-Institutional Cohort Study (YCOG2003)

124. Endometrioid Borderline Ovarian Tumor: Clinical Characteristics, Prognosis, and Managements

125. ASO Visual Abstract: Endometrioid Borderline Ovarian Tumor–Clinical Characteristics, Prognosis, and Management

126. Laparoscopic Ovarian Transposition with Extraperitonealization of the Infundibulopelvic Ligament for Cervical Cancer in Ten Steps

127. ASO Author Reflections: Laparoscopic Ovarian Transposition for Locally Advanced Cervical Cancer—Tailoring the Treatment with the Standardization of a Surgical Procedure

128. Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in the Second Multicenter Selective Lymphadenectomy Trial (MSLT-II)

129. ASO Author Reflections: Minimally Invasive Inguinal Lymphadenectomy, an Incremental Step in the Evolution of the Management of Advanced Melanoma

130. ASO Visual Abstract: Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in MSLT-II

131. Incidence of Second Primary Melanoma in Cutaneous Melanoma Survivors

132. ASO Author Reflections: Counseling Melanoma Survivors on the Risk of a Second Melanoma

133. ASO Visual Abstract: Incidence of Second Primary Melanoma in Survivors of Cutaneous Melanoma

134. Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study

135. ASO Visual Abstract: Evaluation of Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International Multicenter Study

136. Clinically Significant Risk Thresholds in the Management of Primary Cutaneous Melanoma: A Survey of Melanoma Experts

137. ASO Author Reflections: Why Treatment Risk Thresholds Are Needed for Patients with Melanoma

138. ASO Visual Abstract: Clinically Significant Risk Thresholds in the Management of Primary Cutaneous Melanoma: A Survey of Melanoma Experts

139. Real-World Adherence to Nodal Surveillance for Sentinel Lymph Node-Positive Melanoma

140. ASO Author Reflections: Challenges to Achieving Consistent Nodal Surveillance with Ultrasound in Melanoma

141. ASO Visual Abstract: Real-World Adherence to Nodal Surveillance for Sentinel Lymph Node-Positive Melanoma

142. Prognostic Significance of Intraoperative Peritoneal Lavage Cytology in Patients with Pancreatic Ductal Adenocarcinoma: A Single-Center Experience and Systematic Review of the Literature

143. ASO Author Reflections: Positive Status of Intraoperative Peritoneal Lavage Cytology in Patients with Pancreatic Ductal Adenocarcinoma: Are They Candidates for Radical Resection?

144. ASO Visual Abstract: Prognostic Significance of Intraoperative Peritoneal Lavage Cytology in Patients with Pancreatic Ductal Adenocarcinoma: A Single-Center Experience and Systematic Review of the Literature

145. Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer

146. ASO Author Reflections: The Need for Improvement of the 8th American Joint Committee on Cancer TNM Staging System for Resected Pancreatic Ductal Adenocarcinoma

147. ASO Visual Abstract: Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer

148. Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-institutional Analysis from the Central Pancreatic Consortium

149. ASO Author Reflections: Should we Stick our Neck Out for Pancreatic Neck Margins During Pancreaticoduodenectomy After Neoadjuvant Therapy?

150. Downstaging of Pancreatic Adenocarcinoma With Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves Survival

151. ASO Author Reflections: The Impact on Survival of Downstaging by Neoadjuvant Chemotherapy or Chemoradiotherapy in Pancreatic Adenocarcinoma

152. Short- and Long-Term Outcomes of Pancreatic Cancer Resection in Elderly Patients: A Nationwide Analysis

153. ASO Author Reflections: Nationwide Reflection of Clinical Outcomes in Elderly Patients after Resection of Pancreatic Cancer

154. ASO Visual Abstract: Short- and Long-Term Outcomes of Pancreatic Cancer Resection for Elderly Patients: A Nationwide Analysis

155. Correction to: ASO Visual Abstract: Optimizing the Indications for Conversion Surgery Based on an Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study

156. Correction to: MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes

157. Organ-Specific Adverse Effects After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy

158. ASO Author Reflections: Organ-Specific Adverse Effects After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy—A Scoping Review

159. ASO Visual Abstract: Organ-specific Adverse Effects After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy—A Scoping Review